Scleritis in Emergency Medicine 

  • Author: Theodore J Gaeta, DO, MPH, FACEP; Chief Editor: Robert E O'Connor, MD, MPH   more...
 
Updated: Jun 16, 2011
 

Background

Scleritis is an inflammatory disease that affects the sclera; it may be localized, nodular, or diffuse.[1] It may involve the anterior (visible segment) and/or posterior segments of the eye and manifests with redness of the eye and severe eye pain.[2] Isolated posterior scleritis will not present with redness of the visible portion of the eye and may or may not present with pain.

The 4 types of anterior scleritis are as follows:

  1. Diffuse anterior scleritis: This is characterized by widespread inflammation of the anterior portion of the sclera. This is the most common form of anterior scleritis as well as the most benign.
  2. Nodular anterior scleritis: This type is characterized by one or more erythematous, immovable, tender inflamed nodules on the anterior sclera. Approximately 20% of cases progress to necrotizing scleritis.
  3. Necrotizing anterior scleritis with inflammation: This form frequently accompanies serious systemic collagen vascular disorders including rheumatoid arthritis.[3] Pain with this condition is usually extreme, and damage to the sclera is often marked. Necrotizing anterior scleritis with corneal inflammation is also known as sclerokeratitis.
  4. Necrotizing anterior scleritis without inflammation: This type most frequently occurs in patients with long-standing rheumatoid arthritis; it is due to the formation of a rheumatoid nodule in the sclera and is notable for its absence of symptoms. Necrotizing anterior scleritis without inflammation is also known as scleromalacia perforans.

Necrotizing anterior scleritis is the most severe form and most common form of scleritis with vision-threatening complications and resultant permanent visual loss.[4]

Posterior scleritis occurs much less frequently than anterior scleritis, but they may occur concurrently. It has been reported to mimic orbital cellulitis.[5]

In cases of non-necrotizing scleritis, vision is often maintained unless complications such as uveitis occur.[6]

The examiner must be cognizant of conditions that masquerade as scleritis such as toxoplasmosis-induced posterior uveitis and chronic lymphocytic leukemia.[7, 8]Episcleritis often presents similarly to scleritis, but inflammation and erythema is isolated to the episclera, which lies between the sclera and the conjunctiva.[9] Episcleritis has a more benign course and does not cause any visual changes or permanent impairment; however, recurrence is common.

Next

Pathophysiology

The sclera, which consists of collagen and elastic connective tissue, provides a tough protective casing around the eye. Enzymatic degradation of collagen fibrils and invasion of inflammatory cells, including T cells and macrophages, appear to play an important role.

The thickness of the sclera varies from 0.3-1.2 mm. Healthy sclera is consistently white. Inflammation, the principal pathology affecting the sclera, is frequently part of a general inflammatory reaction associated with a systemic immune-mediated collagen vascular disease.[10, 11]

Inflammation of the sclera can progress to ischemia and necrosis, eventually leading to scleral thinning and perforation of the globe. Necrotizing anterior scleritis represents a particularly destructive form of scleritis.

Previous
Next

Epidemiology

Frequency

United States

Scleritis is an uncommon disease. Well-defined incidence rates are hard to find. The prevalence is estimated to be 6 cases per 10,000 population. Of patients diagnosed with scleritis, anterior scleritis is demonstrated in 94% of patients, as opposed to posterior scleritis, which is diagnosed only 6% of the time.

An increased incidence of scleritis has been reported in patients taking bisphosphonates, which are commonly used in the management of osteoporosis.[12]

International

No particular geographic distribution has been noted.

Mortality/Morbidity

  • Morbidity arises from primary scleritis and associated systemic disease.
  • Giant pigment epithelial tear and retinal detachment has been reported in a patient with scleritis.[13]
  • A significant percentage of patients with concurrent scleritis and collagen vascular disease die within 5 years.
  • In 15% of cases, scleritis is the presenting manifestation of collagen vascular disorder and may precede additional symptoms by one to several months.

Race

No published information is available on racial differences.

Sex

The female-to-male ratio is approximately 1.6:1.

Age

  • Cases have been reported in patients ranging from 11-87 years of age. Mean age for all types of scleritis is 52 years.
  • Episcleritis tends to affect younger patients.
Previous
 
 
Contributor Information and Disclosures
Author

Theodore J Gaeta, DO, MPH, FACEP  Clinical Associate Professor, Department of Emergency Medicine, Weill Cornell Medical College; Vice Chairman and Program Director of Emergency Medicine Residency Program, Department of Emergency Medicine, New York Methodist Hospital; Academic Chair, Adjunct Professor, Department of Emergency Medicine, St George's University School of Medicine

Theodore J Gaeta, DO, MPH, FACEP is a member of the following medical societies: Alliance for Clinical Education, American College of Emergency Physicians, Clerkship Directors in Emergency Medicine, Council of Emergency Medicine Residency Directors, New York Academy of Medicine, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Diana Valcich, MD  Staff Physician, Department of Emergency Medicine, New York Methodist Hospital

Diana Valcich, MD is a member of the following medical societies: American College of Emergency Physicians

Disclosure: Nothing to disclose.

Specialty Editor Board

Joseph A Salomone III, MD  Associate Professor and Attending Staff, Truman Medical Centers, University of Missouri-Kansas City School of Medicine; EMS Medical Director, Kansas City, Missouri

Joseph A Salomone III, MD is a member of the following medical societies: American Academy of Emergency Medicine, National Association of EMS Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Gino A Farina, MD, FACEP, FAAEM  Associate Professor of Clinical Emergency Medicine, Albert Einstein College of Medicine; Program Director, Department of Emergency Medicine, Long Island Jewish Medical Center

Gino A Farina, MD, FACEP, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

John D Halamka, MD, MS  Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center

John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Chief Editor

Robert E O'Connor, MD, MPH  Professor and Chair, Department of Emergency Medicine, University of Virginia Health System

Robert E O'Connor, MD, MPH is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Physician Executives, American Heart Association, American Medical Association, Medical Society of Delaware, National Association of EMS Physicians, Society for Academic Emergency Medicine, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Acknowledgments

The authors and editors of eMedicine gratefully acknowledge the contributions of previous authors, Jerome FX Naradzay, MD, Loice Swisher, MD, and Jonathan Adler, MD, to the development and writing of this article.

References
  1. Okhravi N, Odufuwa B, McCluskey P, Lightman S. Scleritis. Surv Ophthalmol. Jul-Aug 2005;50(4):351-63. [Medline].

  2. Wirbelauer C. Management of the red eye for the primary care physician. Am J Med. Apr 2006;119(4):302-6. [Medline]. [Full Text].

  3. Ashok D, Ayliffe WH, Kiely PD. Necrotizing scleritis associated with rheumatoid arthritis: long-term remission with high-dose infliximab therapy. Rheumatology (Oxford). Jul 2005;44(7):950-1. [Medline].

  4. Sainz de la Maza M, Jabbur NS, Foster CS. Severity of scleritis and episcleritis. Ophthalmology. Feb 1994;101(2):389-96. [Medline].

  5. Rossiter-Thornton M, Rossiter-Thornton L, Ghabrial R, Azar DA. Posterior scleritis mimicking orbital cellulitis. Med J Aust. Sep 6 2010;193(5):305-6. [Medline].

  6. Legmann A, Foster CS. Noninfectious necrotizing scleritis. Int Ophthalmol Clin. Winter 1996;36(1):73-80. [Medline].

  7. Bonfioli AA, Orefice F. Toxoplasmosis. Semin Ophthalmol. Jul-Sep 2005;20(3):129-41. [Medline].

  8. Burton BJ, Cunningham ET Jr, Cree IA, Pavesio CE. Eye involvement mimicking scleritis in a patient with chronic lymphocytic leukaemia. Br J Ophthalmol. Jun 2005;89(6):775-6. [Medline].

  9. Watson PG, Hayreh SS. Scleritis and episcleritis. Br J Ophthalmol. Mar 1976;60(3):163-91. [Medline].

  10. Fong LP, Sainz de la Maza M, Rice BA, Kupferman AE, Foster CS. Immunopathology of scleritis. Ophthalmology. Apr 1991;98(4):472-9. [Medline].

  11. Smith JR, Mackensen F, Rosenbaum JT. Therapy insight: scleritis and its relationship to systemic autoimmune disease. Nat Clin Pract Rheumatol. Apr 2007;3(4):219-26. [Medline]. [Full Text].

  12. Leung S, Ashar BH, Miller RG. Bisphosphonate-associated scleritis: a case report and review. South Med J. Jul 2005;98(7):733-5. [Medline].

  13. Thill M, Richard G. Giant pigment epithelial tear and retinal detachment in a patient with scleritis. Retina. Jul-Aug 2005;25(5):667-8. [Medline].

  14. Cazabon S, Over K, Butcher J. The successful use of infliximab in resistant relapsing polychondritis and associated scleritis. Eye. Feb 2005;19(2):222-4. [Medline].

  15. McMullen M, Kovarik G, Hodge WG. Use of topical steroid therapy in the management of nonnecrotizing anterior scleritis. Can J Ophthalmol. Jun 1999;34(4):217-21. [Medline].

  16. Sainz de la Maza M, Jabbur NS, Foster CS. An analysis of therapeutic decision for scleritis. Ophthalmology. Sep 1993;100(9):1372-6. [Medline].

  17. Bauer AM, Fiehn C, Becker MD. Celecoxib, a selective inhibitor of cyclooxygenase 2 for therapy of diffuse anterior scleritis. Am J Ophthalmol. Jun 2005;139(6):1086-9. [Medline].

  18. Ahmadi-Simab K, Lamprecht P, Nölle B, Ai M, Gross WL. Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis. Jul 2005;64(7):1087-8. [Medline].

  19. Boonman ZF, de Keizer RJ, Watson PG. Smoking delays the response to treatment in episcleritis and scleritis. Eye. Sep 2005;19(9):949-55. [Medline].

  20. Deokule S, Saeed T, Murray PI. Deep intramuscular methylprednisolone treatment of recurrent scleritis. Ocul Immunol Inflamm. Feb 2005;13(1):67-71. [Medline].

  21. Fahim K, Houghton O, Dastjerdi M, Mian SI. Posterior scleritis secondary to Pseudomonas aeruginosa keratitis. Cornea. Oct 2005;24(7):879-81. [Medline].

  22. McCluskey P, Wakefield D. Intravenous pulse methylprednisolone in scleritis. Arch Ophthalmol. Jun 1987;105(6):793-7. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.